Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)

Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane) Meeting Abstract

publication date

February 20, 2020

webpage

Web of Science

published in

JOURNAL OF CLINICAL ONCOLOGY Journal

volume

38

issue

6